EMA to Shake Up Staff in 2013

December 28, 2012

The European Medicines Agency (EMA) is planning a significant reorganization in the early months of next year to prepare for policy challenges, including implementing the new falsified medicines legislation.

The reorganization will shift a number of agency staffers from their current roles and will restrict EMA staff from attending events outside the agency until spring 2013 unless they attend via video or teleconference.

EMA Executive Director Guido Rasi said the shift in staff and operations will help prepare for future policy and legislative challenges. In January, new falsified medicines legislation will take effect and later the EMA will consult with stakeholders on a new policy to release clinical trial data. The release of clinical trial data is expected to begin in early 2014.

Enforcement activities, practices and even staff are changing around the globe. The day-to-day routine drugmakers are used to when dealing with international regulators is changing and to be successful, you will need to know as much as possible.

With FDAnews’ Guide to International Pharma Regulation: 2013 Edition, you will receive briefs on regulatory developments affecting pharmaceutical production in more than 45 nations around the world. You also gain access to a compilation of more than 150 reports highlighting changes from the past year that could supercharge your international sales.

To compete internationally, you must comply internationally. It’s a lesson your competitors have learned. Don’t get left behind. Place your advance order now.